also on other fortune lists

company facts

g500 stats

Global 500

Chris Ratcliffe — Bloomberg via Getty Images





Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases–including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

Looking for leads, investment insights, or competitive intelligence?


Ian C. Read


Health Care



HQ Location

New York, NY

Years on Global 500 List




Pfizer is also featured in these fortune lists
Key Financials (Last Fiscal Year)
($ Millions)% change
Revenues ($M)$52,8248.1%
Profits ($M)$7,215.03.7%
Assets ($M)$171,615
Total Stockholder Equity ($M)$59,544
Profit Ratios
Profit as % of Revenues13.7%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity12.1%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Pfizer

An Irish Town That Manufactures Viagra Boasts of 'Love Fumes' in the Air

Ringaskiddy residents say they have an extra spring in their step.

Read More →
The Best Investing Advice for 2018 From Fortune’s Experts

Insights from our annual roundtable on the best stocks and the biggest risks.

Read More →
Pfizer's Viagra Costs Half as Much Starting Today. Here's Why

The "little blue pill" has officially become the "little white pill," and for a big discount.

Read More →
You'll Be Able to Buy Viagra Over the Counter for the First Time Ever—In the U.K.

The little blue pill will finally be available without a prescription.

Read More →
Bill Gates Is Now Tackling Alzheimer’s With a Huge Investment in Dementia Research

He'll put in $50 million to start, with plans to invest at least another $50 million.

Read More →